Fosaprepitant

Drug Profile

Fosaprepitant

Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; Proemend

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiemetics; Morpholines; Small molecules
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • No development reported Postoperative nausea and vomiting

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase-III trial in Chemotherapy-induced nausea and vomiting presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 Mar 2017 Merck terminates phase III trial in Chemotherapy induced nausea and vomiting in (In children, In infants, In neonates, In adolescents) in Portugal, Greece, USA, Sweden, Spain, Finland, Lithuania, Estonia and Hungary, as data from the trial will no longer be required to support an an application for use in paediatric patients (NCT02519842; EudraCT2014-001783-34)
  • 28 Feb 2017 Merck has patent protection for fosaprepitant in Europe and Japan (Merck Annual report 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top